| 35.09 0.88 (2.57%) | 10-09 13:53 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 45.54 | 1-year : | 49.63 |
| Resists | First : | 38.99 | Second : | 42.5 |
| Pivot price | 36.15 |
|||
| Supports | First : | 33.31 | Second : | 27.72 |
| MAs | MA(5) : | 35.03 |
MA(20) : | 37.11 |
| MA(100) : | 34.56 |
MA(250) : | 28.4 |
|
| MACD | MACD : | -0.7 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 12.5 |
D(3) : | 9.7 |
| RSI | RSI(14): 40.2 |
|||
| 52-week | High : | 42.5 | Low : | 15.98 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ROIV ] has closed above bottom band by 23.9%. Bollinger Bands are 9.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 34.64 - 34.85 | 34.85 - 35 |
| Low: | 32.83 - 33.1 | 33.1 - 33.3 |
| Close: | 33.85 - 34.26 | 34.26 - 34.56 |
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
Wed, 07 Oct 2026
Roivant Sciences Ltd. (ROIV) Stock Price, News, Quote & History - Yahoo! Finance Canada
Tue, 06 Oct 2026
Form 4 Roivant Sciences Ltd. For: 6 October By Investing.com - Investing.com Canada
Mon, 05 Oct 2026
Roivant Sciences (ROIV) director exercises $4.46 options and sells 17,750 shares. - Stock Titan
Mon, 05 Oct 2026
Transcript: Roivant Sciences Q1 2027 Earnings Conference Call - Benzinga
Fri, 02 Oct 2026
Through a stock grant settlement, Frank Torti acquires 40,309 Roivant Sciences (ROIV) shares. - Stock Titan
Fri, 02 Oct 2026
CEO Matthew Gline holds 16.6 million shares after Roivant Sciences (ROIV) withholds 76,171 for taxes. - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 722 (M) |
| Held by Insiders | 5.8042e+008 (%) |
| Held by Institutions | 21.4 (%) |
| Shares Short | 36,700 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.36e+009 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -25 % |
| Return on Assets (ttm) | 408.1 % |
| Return on Equity (ttm) | -16.5 % |
| Qtrly Rev. Growth | 7.53e+006 % |
| Gross Profit (p.s.) | -29.92 |
| Sales Per Share | -7.61 |
| EBITDA (p.s.) | -6.4633e+008 |
| Qtrly Earnings Growth | -0.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -816 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -4.59 |
| Price to Cash Flow | 6.66 |
| Dividend | 0 |
| Forward Dividend | 3.06e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|